文献速递骨质疏松与代谢性骨病

特立帕肽治疗后骨改建药物的效果

Effects of bone remodeling agents following teriparatide treatment.
PubMed 文献 · Osteoporos Int · 2018-03-14

本研究为回顾性队列研究,纳入94例有脆性骨折史并完成2年特立帕肽治疗的患者,最终64例纳入分析,比较后续使用唑来膦酸、地舒单抗或无治疗2年对骨密度的影响。结果显示地舒单抗组腰椎骨密度增加4.94%±8.2%、股骨颈增加5.68%±6.7%,为增幅最大组;停止治疗者骨密度变化较特立帕肽治疗期间显著下降。

要点

  • 特立帕肽治疗2年后改用地舒单抗2年,腰椎骨密度增加4.94%±8.2%,股骨颈增加5.68%±6.7%。
  • 地舒单抗组骨密度增幅在股骨颈和腰椎均统计学显著大于无治疗组和唑来膦酸组。
  • 停用骨质疏松治疗者骨密度变化较特立帕肽治疗期间显著下降,脆性骨折复发风险更高。

核心结论

  • 特立帕肽治疗后改用地舒单抗的患者骨密度增幅最大。
  • 选择停止骨质疏松治疗的患者骨密度变化较特立帕肽治疗期间显著下降,脆性骨折复发风险更高。

研究设计与样本

  • 回顾性队列研究,从一家与一级创伤中心关联的骨骼健康门诊识别94例有脆性骨折史的患者。
  • 所有参与者均在2008年至2013年间完成2年特立帕肽治疗,随后接受2年唑来膦酸、地舒单抗或无治疗。
  • 排除实验室数据不足者后,最终64例纳入分析。

主要发现

  • 完成特立帕肽治疗后,开始地舒单抗的患者在治疗2年后骨密度增幅最大:腰椎4.94%±8.2%,股骨颈5.68%±6.7%。
  • 地舒单抗组股骨颈和腰椎骨密度增幅统计学显著大于无治疗组和唑来膦酸组。
  • 选择停止骨质疏松治疗的患者骨密度变化较特立帕肽治疗期间显著下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Teriparatide is an anabolic therapy used to treat patients with osteoporosis and is only approved for 2 years of treatment. This is the first study to look at two common osteoporosis drugs in maintaining its beneficial effects: denosumab and zoledronic acid. Denosumab treatment was associated with the greatest increase in bone mineral density (BMD) at the femoral neck and lumbar spine, an amount that was statistically greater than no treatment and zoledronic acid treatment. INTRODUCTION: Teriparatide, a hallmark treatment for osteoporosis, has been shown to increase BMD and bone turnover. This can be measured using BMD scans, N-terminal propeptide of type-1 collagen (P1NP) for bone formation and C-terminal telopeptide (CTX) for bone resorption. This study examines the effects of the two most common antiresorptive drugs prescribed following 2 years of teriparatide treatment: zoledronic acid and denosumab. The purpose of this study is to quantify the beneficial effects of teriparatide and compare the ability of each antiresorptive drug to maintain the effects. METHODS: Ninety-four patients with prior fragility fractures were identified from a bone health clinic associated with a level I trauma center. All of the study participants completed 2 years of treatment with teriparatide between 2008 and 2013 followed by 2 years of treatment with zoledronic acid, denosumab, or no treatment. After excluding patients with insufficient laboratory data, 64 patients remained for analysis in this retrospective cohort study. Bone mineral density was measured in the lumbar spine and femoral neck. RESULTS: Following completion of teriparatide, patients who were started on denosumab showed the largest increase in bone mineral density after 2 years of treatment: lumbar spine 4.94% ± 8.2%, femoral neck 5.68% ± 6.7%. CONCLUSIONS: Patients who elected to discontinue osteoporosis treatment experienced a significant decline in the change in BMD compared to the change on teriparatide putting them at higher risk for recurrence of fragility fractures. Patients on denosumab following teriparatide had the largest increase in BMD.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Burkard D, Beckett T, Kourtjian E, et al. Effects of bone remodeling agents following teriparatide treatment. Osteoporos Int. 2018. PMID: 29541794. doi:10.1007/s00198-018-4434-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。